


# Small Molecule Drug Discovery



Australia is ideally positioned to be a major player in the global Pharma ecosystem where risk-averse companies are looking to in-license assets that have demonstrated development potential.

To enhance the progression of early stage discoveries through to preclinical development, TIA has formed a Small Molecules Group, an integrated capability network of National Research Infrastructure across Australia.

These facilities are committed to providing high quality research infrastructure to support leading-edge research and to boost innovation in Australia.



THE THERAPEUTIC  
INNOVATION  
AUSTRALIA

SUPPORTED BY:

**NCRIS**

National Research  
Infrastructure for Australia

An Australian Government Initiative

CONTACT US:

T: (07) 3735 4433

E: [info@therapeuticinnovation.com.au](mailto:info@therapeuticinnovation.com.au)

Level 14, 330 Collins Street,  
Melbourne VIC 3000

[www.therapeuticinnovation.com.au](http://www.therapeuticinnovation.com.au)

## Compounds Australia

### Capability/services offered:

- National compound management and logistics facility for small molecule compound libraries and natural product extract and fraction libraries.
- Cost effective compound management, supporting drug discovery through high throughput screening
- Provides storage and management of the national open access compound collection, GRIDD's NatureBank collection and numerous proprietary compound collections.

*Website: [compoundsaustralia.com](http://compoundsaustralia.com)*



## TIA Pipeline Accelerator

### Capability/services offered:

- Provides access to support funding to research groups for meritorious projects, identified through an open call, with the intention of supporting that project's access to at least one Pipeline-member facility
- High throughput screening (HTS) campaigns to be supported through a competitive scheme that awards access vouchers of a set value to researchers seeking to access HTS capabilities

*Website: [therapeuticinnovation.com.au/accelerator](http://therapeuticinnovation.com.au/accelerator)*



## Australian Translational Medicinal Chemistry Facility

### Capability/services offered:

- Optimisation of screening hits and lead compounds
- Mechanism- or substrate-based design and synthesis of enzyme inhibitors
- Advice on drug discovery strategy including literature/patent searching
- Custom synthesis of known/novel compounds
- Other chemistry needs eg. targeted drug delivery and novel linker design and synthesis

*Website: [monash.edu/atmcf](http://monash.edu/atmcf)*



## Centre for Drug Candidate Optimisation

### Capability/services offered:

- Integrated in vitro studies to assess absorption, distribution, metabolism and excretion (ADME)
- Physicochemical profiling and characterisation
- Drug metabolism, metabolite identification, and assessment of metabolic drug interactions
- Assessment of permeability and binding properties
- Small animal pharmacokinetic studies to determine clearance mechanisms and oral bioavailability
- Discovery stage bioanalysis by LC MS/MS

*Website: [platforms.monash.edu/cdco/](http://platforms.monash.edu/cdco/)*



## Centre for Integrated Preclinical Drug Development

### Capability/services offered:

- Preclinical efficacy studies in rodent models of human disease
- New rodent models of human disease in response to collaborator need
- Training of research students in related techniques

*Website: [biomedical-sciences.uq.edu.au/cipdd](http://biomedical-sciences.uq.edu.au/cipdd)*



## TetraQ

### Capability/services offered:

- Pharmacokinetics and screening toxicology studies in rodents to support preclinical development
- GLP toxicology and toxicokinetics studies in rodents to enable first-in-human clinical studies

*Website: [tetraq.com.au](http://tetraq.com.au)*

